$AVDL
AVADEL PHARMACEUTICALS PLC Stock $avdl

$avdl Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000101247723000023 Filed on November 08, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2022 Q3
Revenue	$19.45M	$7.014M	$0.00
YoY Change
Cost Of Revenue	$693.0K	$117.0K	$0.00
YoY Change
Gross Profit	$18.76M	$6.897M	$0.00
YoY Change
Gross Profit Margin	96.44%	98.33%
Selling, General & Admin	$41.30M	$39.16M	$14.10M
YoY Change	143.22%	177.8%	-33.77%
% of Gross Profit	220.15%	567.75%
Research & Development	$2.359M	$2.849M	$2.933M
YoY Change	-62.17%	-2.86%	-33.04%
% of Gross Profit	12.57%	41.31%
Depreciation & Amortization	-$14.00K	$590.0K	$401.0K
YoY Change	-102.39%	47.13%	103.55%
% of Gross Profit	-0.07%	8.55%
Operating Expenses	$43.66M	$42.01M	$17.03M
YoY Change	88.06%	146.68%	-33.64%
Operating Profit	-$24.90M	-$35.11M	-$16.96M
YoY Change		107.02%	-33.91%
Interest Expense	-$2.354M	-$1.980M	-$3.564M
YoY Change	-27.68%	-44.44%	84.76%
% of Operating Profit
Other Income/Expense, Net	-$1.632M	$900.0K	$448.0K
YoY Change	52.24%	100.89%
Pretax Income	-$28.89M	-$36.19M	-$20.08M
YoY Change	5.56%	80.24%	-25.93%
Income Tax	-$100.0K	$89.00K	$70.00K
% Of Pretax Income
Net Earnings	-$28.79M	-$36.27M	-$20.15M
YoY Change	4.87%	80.06%	-8.44%
Net Earnings / Revenue	-147.98%	-517.17%
Basic Earnings Per Share		-$0.41	-$0.33
Diluted Earnings Per Share	-$0.32	-$0.41	-$0.33
COMMON SHARES
Basic Shares Outstanding	89.81M shares	89.37M shares	59.79M shares
Diluted Shares Outstanding		89.38M shares	60.20M shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$105.1M	$153.2M	$106.5M
YoY Change	8.92%	43.88%	-41.2%
Cash & Equivalents	$31.17M	$51.81M	$60.72M
Short-Term Investments	$73.94M	$101.4M	$45.76M
Other Short-Term Assets	$913.0K	$779.0K	$567.0K
YoY Change	300.44%	37.39%	48.43%
Inventory	$10.38M	$5.286M
Prepaid Expenses	$4.373M	$5.504M	$3.745M
Receivables	$12.10M	$6.239M	$277.0K
Other Receivables	$1.322M	$1.300M	$2.158M
Total Short-Term Assets	$134.2M	$172.3M	$113.2M
YoY Change	33.08%	52.14%	-44.99%
LONG-TERM ASSETS
Property, Plant & Equipment	$585.0K	$648.0K	$896.0K
YoY Change	-30.27%	-27.68%	194.74%
Goodwill	$16.84M	$16.84M	$16.84M
YoY Change	0.0%	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$10.15M	$10.15M	$11.72M
YoY Change	-10.33%	-13.41%	-69.24%
Total Long-Term Assets	$30.50M	$30.85M	$32.54M
YoY Change	-4.53%	-5.2%	-44.16%
TOTAL ASSETS
Total Short-Term Assets	$134.2M	$172.3M	$113.2M
Total Long-Term Assets	$30.50M	$30.85M	$32.54M
Total Assets	$164.7M	$203.1M	$145.8M
YoY Change	24.03%	39.34%	-44.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$11.43M	$13.26M	$2.479M
YoY Change	44.9%	435.01%	-63.94%
Accrued Expenses	$24.23M	$17.96M	$7.965M
YoY Change	230.34%	125.45%	-8.85%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$21.19M	$26.30M
YoY Change	-100.0%	-19.44%
Total Short-Term Liabilities	$36.86M	$54.05M	$41.51M
YoY Change	-33.94%	30.22%	136.03%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$109.9M
YoY Change	-100.0%	-100.0%	-22.63%
Other Long-Term Liabilities	$5.654M	$5.818M	$5.727M
YoY Change	-1.55%	1.59%	43.21%
Total Long-Term Liabilities	$5.654M	$5.818M	$115.7M
YoY Change	-94.19%	-94.97%	-20.83%
TOTAL LIABILITIES
Total Short-Term Liabilities	$36.86M	$54.05M	$41.51M
Total Long-Term Liabilities	$5.654M	$5.818M	$115.7M
Total Liabilities	$76.96M	$92.95M	$158.2M
YoY Change	-50.0%	-41.24%	-4.2%
SHAREHOLDERS EQUITY
Retained Earnings	-$745.5M	-$716.7M	-$557.8M
YoY Change	27.39%	28.5%	31.1%
Common Stock	$856.4M	$852.8M	$573.2M
YoY Change	45.04%	48.76%	4.77%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$87.74M	$110.1M	-$12.44M
YoY Change
Total Liabilities & Shareholders Equity	$164.7M	$203.1M	$145.8M
YoY Change	24.03%	39.34%	-44.81%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2022 Q3
OPERATING ACTIVITIES
Net Income	-$28.79M	-$36.27M	-$20.15M
YoY Change	4.87%	80.06%	-8.44%
Depreciation, Depletion And Amortization	-$14.00K	$590.0K	$401.0K
YoY Change	-102.39%	47.13%	103.55%
Cash From Operating Activities	-$28.03M	-$38.22M	-$6.803M
YoY Change	82.42%	461.81%	-67.97%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	-$716.0K
YoY Change		-100.0%
Acquisitions
YoY Change
Other Investing Activities	$27.93M	$9.820M	$3.240M
YoY Change	22.09%	203.09%	-73.65%
Cash From Investing Activities	$27.93M	$9.820M	$2.524M
YoY Change	22.09%	289.06%	-79.47%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-21.11M	30.46M	10.72M
YoY Change	-418.86%	184.27%	9299.12%
NET CHANGE
Cash From Operating Activities	-28.03M	-38.22M	-6.803M
Cash From Investing Activities	27.93M	9.820M	2.524M
Cash From Financing Activities	-21.11M	30.46M	10.72M
Net Change In Cash	-21.22M	2.060M	6.436M
YoY Change	-250.16%	-67.99%	-172.89%
FREE CASH FLOW
Cash From Operating Activities	-$28.03M	-$38.22M	-$6.803M
Capital Expenditures	$0.00	$0.00	-$716.0K
Free Cash Flow	-$28.03M	-$38.22M	-$6.087M
YoY Change	82.42%	527.9%	-71.34%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Security12b Title Security12bTitle	Ordinary Shares, nominal value $0.01 per share**
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	89805653	shares
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8510000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	153000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0	usd
	us-gaap	Gross Profit GrossProfit	8357000	usd
	us-gaap	Gross Profit GrossProfit	0	usd
CY2023Q3	us-gaap	Costs And Expenses CostsAndExpenses	42007000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-75523000	usd
	us-gaap	Investment Income Net InvestmentIncomeNet	1719000	usd
	us-gaap	Investment Income Net InvestmentIncomeNet	536000	usd
CY2022Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	3564000	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	7532000	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	9087000	usd
CY2023Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-13129000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-20076000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-131891000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-84074000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	89000	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	70000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-401000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	25940000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-36274000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-20146000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-131490000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-110014000	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.41
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.33
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.71
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.85
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.41
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.33
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.71
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.85
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	89380000	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60201000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	76931000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	76931000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	76931000	shares
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-36274000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-20146000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-131490000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-8000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1581000	usd
CY2023Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	21187000	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	916000	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	13263000	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	17957000	usd
CY2023Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	731000	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	54054000	usd
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	5194000	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	89398000	shares
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-26424000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1102000	usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001012477
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Amendment Flag AmendmentFlag	false
	dei	No Trading Symbol Flag NoTradingSymbolFlag	true
CY2023Q2	avdl	American Depository Shares Conversion Ratio AmericanDepositorySharesConversionRatio	0.1161846
CY2023Q2	avdl	American Depository Shares Conversion Ratio AmericanDepositorySharesConversionRatio	0.1161846
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10902000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14465000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	110404000	usd
CY2023Q3	us-gaap	Restructuring Charges RestructuringCharges	0	usd
CY2022Q3	us-gaap	Restructuring Charges RestructuringCharges	-69000	usd
CY2022Q3	us-gaap	Costs And Expenses CostsAndExpenses	16960000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	121306000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	75523000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-36185000	usd
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	59359000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	89380000	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	60201000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	59359000	shares
	us-gaap	Net Income Loss NetIncomeLoss	-110014000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-303000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-647000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-120000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-1489000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	usd
CY2022Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	usd
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	5194000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	488000	shares
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	usd
CY2023Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	295000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-934000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	511000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-2480000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	391000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-3969000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-36282000	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-21727000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-131099000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-113983000	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	51811000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	73981000	usd
CY2023Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	101368000	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	22518000	usd
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6239000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	5286000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	0	usd
CY2023Q3	avdl	Research And Development Tax Credit Receivable Current ResearchAndDevelopmentTaxCreditReceivableCurrent	1199000	usd
CY2022Q4	avdl	Research And Development Tax Credit Receivable Current ResearchAndDevelopmentTaxCreditReceivableCurrent	2248000	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6352000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2096000	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	172255000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	100843000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	648000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	839000	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2804000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1713000	usd
CY2023Q3	us-gaap	Goodwill Goodwill	16836000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	16836000	usd
CY2023Q3	avdl	Research And Development Tax Credit Receivable Non Current ResearchAndDevelopmentTaxCreditReceivableNonCurrent	409000	usd
CY2022Q4	avdl	Research And Development Tax Credit Receivable Non Current ResearchAndDevelopmentTaxCreditReceivableNonCurrent	1232000	usd
CY2023Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	10148000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	11322000	usd
CY2023Q3	us-gaap	Assets Assets	203100000	usd
CY2022Q4	us-gaap	Assets Assets	132785000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	37668000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	960000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7890000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7334000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1941000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	55793000	usd
CY2023Q3	us-gaap	Senior Long Term Notes SeniorLongTermNotes	0	usd
CY2022Q4	us-gaap	Senior Long Term Notes SeniorLongTermNotes	91614000	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1928000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	780000	usd
CY2023Q3	avdl	Royalty Financing Liability Noncurrent RoyaltyFinancingLiabilityNoncurrent	31151000	usd
CY2022Q4	avdl	Royalty Financing Liability Noncurrent RoyaltyFinancingLiabilityNoncurrent	0	usd
CY2023Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5818000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5743000	usd
CY2023Q3	us-gaap	Liabilities Liabilities	92951000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	153930000	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	488000	shares
CY2023Q3	us-gaap	Preferred Stock Value PreferredStockValue	52000	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	5000	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	89398000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	62878000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	62878000	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	893000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	628000	usd
CY2023Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	851865000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	589783000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-716710000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-585220000	usd
CY2023Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-25951000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-26341000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-21145000	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	203100000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	132785000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-21145000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-30784000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	315000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	11913000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	16000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	29000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1522000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-38166000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-64432000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	83000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	134151000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	102162000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1750000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7644000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	143192000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-36274000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-8000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	261000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	201000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3127000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	110149000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	78244000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1906000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	0	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	103000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2505000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	55232000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-63444000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1286000	usd
CY2022Q2	avdl	Adjustments To Additional Paid In Capital Adjustments In Fair Value Of Convertible Debt Conversion Feature AdjustmentsToAdditionalPaidInCapitalAdjustmentsInFairValueOfConvertibleDebtConversionFeature	5508000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	658000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-3332000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-20146000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1581000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	64000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	10532000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	19000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	119000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1923000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-12440000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-131490000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-110014000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1784000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	907000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	2796000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	4147000	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	25916000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	12293000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	5086000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-13129000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-349000	usd
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	1506000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	6239000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5286000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4277000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-27948000	usd
	avdl	Increase Decrease In Research And Development Tax Credit Receivable IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable	-1918000	usd
	avdl	Increase Decrease In Research And Development Tax Credit Receivable IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable	-27000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3837000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-11629000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	10621000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	4277000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets And Liabilities Net IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet	-781000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets And Liabilities Net IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet	3109000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-100482000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-54938000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	716000	usd
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	125498000	usd
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	59873000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	203519000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	2334000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-78021000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	56823000	usd
	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	17500000	usd
	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	0	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	4357000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	4803000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	30000000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	2241000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	2192000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	156446000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7921000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-113000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	201000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-22170000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	10007000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	73981000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	50708000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	51811000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	60715000	usd
	us-gaap	Interest Paid Net InterestPaidNet	4520000	usd
	us-gaap	Interest Paid Net InterestPaidNet	9660000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-32323000	usd
CY2023Q2	avdl	Orphan Drug Exclusivity Term OrphanDrugExclusivityTerm	P7Y
CY2023Q1	avdl	Royalty Financing Proceeds Maximum RoyaltyFinancingProceedsMaximum	75000000	usd
CY2023Q1	avdl	Royalty Financing Quarterly Net Revenue Target RoyaltyFinancingQuarterlyNetRevenueTarget	25000000	usd
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q2	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	134151000	usd
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q2	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	12347000	shares
CY2023Q2	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	1470000	usd
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	Reclassifications<span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications are made to prior year amounts whenever necessary to conform with the current year presentation. Certain reclassifications have been made to balances within the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Condensed Consolidated Statements of Cash Flows</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the nine months ended September 30, 2022 and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9: Other Assets and Liabilities</span> for the year ended December 31, 2022 to condense line items of the same nature into a single line.
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	usd
CY2023Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	102747000	usd
CY2023Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	830000	usd
CY2023Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2209000	usd
CY2023Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	101368000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	24407000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1889000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	22518000	usd
CY2023Q3	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	268000	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	64000	usd
CY2023Q3	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	283000	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	61000	usd
	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	269000	usd
	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	372000	usd
	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	344000	usd
	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	1092000	usd
CY2023Q3	us-gaap	Inventory Raw Materials And Supplies Net Of Reserves InventoryRawMaterialsAndSuppliesNetOfReserves	2591000	usd
CY2023Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	299000	usd
CY2023Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2396000	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	5286000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	0	usd
CY2022Q2	avdl	Debt Instrument Convertible Embedded Conversion Feature Increase Decrease DebtInstrumentConvertibleEmbeddedConversionFeatureIncreaseDecrease	5508000	usd
CY2022Q2	avdl	Adjustments To Additional Paid In Capital Adjustments In Fair Value Of Convertible Debt Conversion Feature AdjustmentsToAdditionalPaidInCapitalAdjustmentsInFairValueOfConvertibleDebtConversionFeature	5508000	usd
CY2022Q2	avdl	Debt Instrument Convertible Embedded Conversion Feature Increase Decrease DebtInstrumentConvertibleEmbeddedConversionFeatureIncreaseDecrease	5508000	usd
CY2018Q1	avdl	American Depository Shares Conversion Ratio AmericanDepositorySharesConversionRatio	92.6956
CY2023Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-13129000	usd
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q2	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	12347000	shares
CY2023Q2	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	1470000	usd
CY2023Q1	avdl	Royalty Financing Proceeds Maximum RoyaltyFinancingProceedsMaximum	75000000	usd
CY2023Q1	avdl	Royalty Financing Quarterly Net Revenue Target RoyaltyFinancingQuarterlyNetRevenueTarget	25000000	usd
CY2023Q1	avdl	Royalty Financing Quarterly Royalty Payment Percentage RoyaltyFinancingQuarterlyRoyaltyPaymentPercentage	0.0375
CY2023Q1	avdl	Royalty Financing Proceeds Maximum RoyaltyFinancingProceedsMaximum	75000000	usd
CY2023Q1	avdl	Royalty Financing Proceeds Maximum RoyaltyFinancingProceedsMaximum	75000000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	89000	usd
CY2023Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.002
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	70000	usd
CY2022Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.003
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-401000	usd
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.003
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	25940000	usd
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.309
CY2023Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	5504000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1523000	usd
CY2023Q3	us-gaap	Other Assets Current OtherAssetsCurrent	779000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	504000	usd
CY2023Q3	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	69000	usd
CY2022Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	69000	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6352000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2096000	usd
CY2023Q3	avdl	Operating Lease Right Of Use Asset Contract Manufacturing Noncurrent OperatingLeaseRightOfUseAssetContractManufacturingNoncurrent	9804000	usd
CY2022Q4	avdl	Operating Lease Right Of Use Asset Contract Manufacturing Noncurrent OperatingLeaseRightOfUseAssetContractManufacturingNoncurrent	10686000	usd
CY2023Q3	avdl	Other Noncurrent Receivables OtherNoncurrentReceivables	344000	usd
CY2022Q4	avdl	Other Noncurrent Receivables OtherNoncurrentReceivables	636000	usd
CY2023Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	10148000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	11322000	usd
CY2023Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	10092000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	4040000	usd
CY2023Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	6068000	usd
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1613000	usd
CY2023Q3	avdl	Accrued Trade Discounts And Rebates AccruedTradeDiscountsAndRebates	1347000	usd
CY2022Q4	avdl	Accrued Trade Discounts And Rebates AccruedTradeDiscountsAndRebates	0	usd
CY2023Q3	avdl	Royalty Financing Liability Current RoyaltyFinancingLiabilityCurrent	253000	usd
CY2022Q4	avdl	Royalty Financing Liability Current RoyaltyFinancingLiabilityCurrent	0	usd
CY2023Q3	avdl	Accrued Outsource Contract Costs AccruedOutsourceContractCosts	197000	usd
CY2022Q4	avdl	Accrued Outsource Contract Costs AccruedOutsourceContractCosts	1208000	usd
CY2023Q3	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	0	usd
CY2022Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	473000	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	17957000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7334000	usd
CY2023Q3	avdl	Accrued Interest Current AccruedInterestCurrent	462000	usd
CY2022Q4	avdl	Accrued Interest Current AccruedInterestCurrent	1649000	usd
CY2023Q3	avdl	Other Liabilities Miscellaneous Current OtherLiabilitiesMiscellaneousCurrent	269000	usd
CY2022Q4	avdl	Other Liabilities Miscellaneous Current OtherLiabilitiesMiscellaneousCurrent	292000	usd
CY2023Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	731000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1941000	usd
CY2023Q3	avdl	Tax Liabilities And Other Noncurrent Liabilities TaxLiabilitiesAndOtherNoncurrentLiabilities	5508000	usd
CY2022Q4	avdl	Tax Liabilities And Other Noncurrent Liabilities TaxLiabilitiesAndOtherNoncurrentLiabilities	5246000	usd
CY2023Q3	us-gaap	Guaranty Liabilities GuarantyLiabilities	310000	usd
CY2022Q4	us-gaap	Guaranty Liabilities GuarantyLiabilities	497000	usd
CY2023Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5818000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5743000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-36274000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-20146000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-131490000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-110014000	usd
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	89380000	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60201000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	76931000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	76931000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	59359000	shares
CY2023Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2022Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	89380000	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	60201000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	76931000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	59359000	shares
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.41
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.33
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.71
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.85
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.41
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.33
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.71
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.85
CY2023Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2509000	shares
CY2022Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	18722000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5336000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	18925000	shares
CY2023Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	usd
CY2022Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	usd
	avdl	Percentage Of Royalty Payable On Net Sales PercentageOfRoyaltyPayableOnNetSales	0.15
CY2023Q3	us-gaap	Guarantee Obligations Current Carrying Value GuaranteeObligationsCurrentCarryingValue	570000	usd
CY2023Q3	avdl	Guarantee Asset Current Carrying Value GuaranteeAssetCurrentCarryingValue	564000	usd
CY2023Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false

Files In Submission

Name	View Source	Status
avdl-20230930_def.xml	Edgar Link	unprocessable
avdl-20230930_pre.xml	Edgar Link	unprocessable
avdl-20230930_cal.xml	Edgar Link	unprocessable
avdl-20230930_lab.xml	Edgar Link	unprocessable
0001012477-23-000023-index-headers.html	Edgar Link	pending
0001012477-23-000023-index.html	Edgar Link	pending
0001012477-23-000023.txt	Edgar Link	pending
0001012477-23-000023-xbrl.zip	Edgar Link	pending
avdl-20230930.htm	Edgar Link	pending
avdl-20230930.xsd	Edgar Link	pending
exhibit311q32023.htm	Edgar Link	pending
exhibit312q32023.htm	Edgar Link	pending
exhibit321q32023.htm	Edgar Link	pending
exhibit322q32023.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
avdl-20230930_htm.xml	Edgar Link	completed
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AVDL
AVADEL PHARMACEUTICALS PLC Stock $avdl

2023 Q4 Form 10-Q Financial Statement

#000101247723000023 Filed on November 08, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVDL AVADEL PHARMACEUTICALS PLC Stock $avdl

2023 Q4 Form 10-Q Financial Statement

#000101247723000023 Filed on November 08, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVDL
AVADEL PHARMACEUTICALS PLC Stock $avdl